Showing posts with label Molecular Biology. Show all posts
Showing posts with label Molecular Biology. Show all posts

Daily Science Journal (Feb. 2, 2008) — While biomedical, electronics, and other branches of research are marching steadily into the realm of the smaller-than-small nanometer scale, building needed materials at this scale has been problematic.

Recently, however, a team from The Scripps Research Institute unveiled a novel approach to the problem that yields a material with novel properties, which some might find reminiscent of Flubber. The material is produced using naturally occurring proteins as templates for uniform, self-assembled, nano-scale construction.

The material, an organic polymer described in today's early, online edition of the Proceedings of the National Academy of Sciences (PNAS), could one day find application in everything from screening for disease to microelectronics.


Using Nature's Tricks

Nature is replete with examples of molecules such as DNA that self-assemble with uniform patterns on the nanoscale, but until now researchers have had limited success duplicating such processes. The new study, however, provides one synthetic method that has effectively mimicked the templating strategy used in nature for nanoscale construction in the lab.

To create the new material, the Scripps Research team, led by Scripps Research President Richard Lerner and Assistant Professor Tobin Dickerson, began with a natural nanoscale product, a bacterial virus or phage. A nanometer is one billionth of a meter, or the width of a few average atoms.

Specifically, the product the team worked with was a phage known as M13. If scaled up, the phage is proportionally equivalent to a 4-foot-long pencil, with the tip and eraser roughly representing the active parts of the phage that infect bacteria. Other proteins that are biologically inert and analogous to the wood body of the pencil provide the filamentous phage's structure.

Having worked with phage extensively in other applications, the team decided to explore the possibility of using those structural proteins as a potential template for nanoscale construction. To do so, the team chemically modified molecular protrusions on the proteins so they would attract and bind with the components needed to form strands of polyacrylamide, a common polymer used to make laboratory gels.

The resulting polymer-phage combination, which twists into helices like DNA and RNA molecules, takes on the shape of a comb with the polymers as the teeth. These teeth in turn interlock to form a strangely resilient, rubbery solid.

Shocking Flexibility

Once the new material, known as a protein-polymer bioconjugate, was created, the group was shocked to find that it was almost impossible to break a sample apart. It could be sliced, but no matter how hard researchers compressed or squeezed it, it always bounced back to its original state, because the stable phage proteins act like rebar in concrete to provide strength.

Further analyses uncovered additional important characteristics. The combs do not grow completely uniformly—some combs grow more teeth than others, for instance, before interlocking with a nearby comb. But the combs can only be a prescribed distance apart for the chemical interlocking to occur, which leads to uniform size for the pores between the comb teeth. The pores proved to be about 4 nanometers wide and greater than 1 micrometer (one millionth of a meter) in length.

This uniformity is in stark contrast with experiments which showed that simply mixing the phages with polymers without the templating procedure produces a chaotic hodge podge at the molecular level.

Interestingly, after creating the material, the group discovered that a British scientist had done theoretical calculations about how flexible rods—like the phages—would pack together using the least amount of energy.

"It was extremely gratifying to see that the mathematics had exactly predicted what we were observing," says Dickerson

Putting It to Use

Although the work was intended mainly as a proof of concept for using the phages as templates, the researchers have a number of potential applications in mind. The phage can be produced easily and cheaply in very large quantities, and the polymer components are readily available and simple to combine to create the final material. These characteristics would make commercial application possible.

"In essence, bacteriophage-derived materials are a renewable resource," says Dickerson.

The defined channels established by the pores in the material might be adapted as pathways for electrons for use in microelectronics. Or, the pores might be used as a filter for certain molecules, for example to test blood samples for proteins whose presence is tied to particular diseases. More complex potential uses might include altering the biologically active portions of the phage to attract specific molecules, forcing them into the polymers' pores, or to block others.

"These tools can be visualized like Tinkertoys ® or Legos ®," says Dickerson of the possibilities. "You can think about this really in engineering terms using macroscopic analogs such as baskets, or lids, or holes."

To add to the list of potential applications, the team has already begun exploring additional materials that might be created using the basic phage construction scheme.

In addition to Dickerson and Lerner, authors on the paper, entitled "Biologically templated organic polymers with nanoscale order," were Bert Willis, Lisa Eubanks, Malcolm Wood, and Kim Janda, all of Scripps Research. See http://www.pnas.org/cgi/content/abstract/0711308105v1.

The work was supported by the Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine, and a National Institutes of Health Kirschstein National Research Service Award.

Adapted from materials provided by Scripps Research Institute.



Read the rest of this entry »

Daily Science Journal (Jan. 16, 2008) — Green tea may help protect against autoimmune disease, Medical College of Georgia researchers say.

Dr Stephen Hsu and colleagues found that green tea may help protect against autoimmune disease. (Credit: Image courtesy of Medical College of Georgia)

Researchers studied an animal model for type I diabetes and primary Sjogren’s Syndrome, which damages the glands that produce tears and saliva.

They found significantly less salivary gland damage in a group treated with green tea extract, suggesting a reduction of the Sjogren’s symptom commonly referred to as dry mouth. Dry mouth can also be caused by certain drugs, radiation and other diseases.

Approximately 30 percent of elderly Americans suffer from degrees of dry mouth, says Dr. Stephen Hsu, a researcher in the MCG School of Dentistry and lead investigator on the study. Only 5 percent of the elderly in China, where green tea is widely consumed, suffer from the problem.


“Since it is an autoimmune disease, Sjogren’s Syndrome causes the body to attack itself and produce extra antibodies that mistakenly target the salivary and lacrimal glands,” he says. There is no cure or prevention for Sjogren’s Syndrome.

Researchers studied the salivary glands of the water-consuming group and a green tea extract-consuming group to look for inflammation and the number of lymphocytes, a type of white blood cells that gather at sites of inflammation to fend off foreign cells.

The group treated with green tea had significantly fewer lymphocytes, Dr. Hsu says. Their blood also showed lower levels of autoantibodies, protein weapons produced when the immune system attacks itself, he says.

Researchers already know that one component of green tea – EGCG – helps suppress inflammation, according to Dr. Hsu. "So, we suspected that green tea would suppress the inflammatory response of this disease. Those treated with the green tea extract beginning at three weeks, showed significantly less damage to those glands over time.”

Researchers also suspect that the EGCG in green tea can turn on the body’s defense system against TNF-alpha – a group of proteins and molecules involved in systemic inflammation. TNF-alpha, which is produced by white blood cells, can reach out to target and kill cells.

“The salivary gland cells treated with EGCG had much fewer signs of cell death caused by TNF-alpha,” Dr. Hsu says. “We don’t yet know exactly how EGCG makes that happen. That will require further study. In some ways, this study gives us more questions than answers.”

These results, published in a recent issue of Autoimmunity, reinforced findings of a 2005 study showing a similar phenomenon in a Petrie dish, Dr. Hsu says. Further study could help determine green tea’s protective role in other autoimmune diseases, including lupus, psoriasis, scleroderma and rheumatoid arthritis, he says.

Adapted from materials provided by Medical College of Georgia.

--------------------------------------------------------------------------------

Add On Article :

Cup Of Green Tea To Keep The Bacteria Away

Beneficial effects of green tea have been known for millenia, particularly in Asian cultures. An ancient Chinese proverb says: "Better to be deprived of food for three days, than tea for one". A cup of green tea contains up to 200 mg of catechins, whose biological activity has been mainly attributed to its antioxidant activity. Efficiency of green tea extract in oral hygiene has been known for centuries and this gave researchers a clue that antibacterial activity might be involved.

Now researchers from the National institute of Chemistry in Ljubljana, Slovenia discovered that the main ingredients of green tea are able to perform other tricks. They found out that green tea catechins inhibit essential bacterial enzyme DNA gyrase, which is the target of several existing clinically used drugs. By the use of NMR spectroscopy, researchers from Slovenia have now pinpointed the ATP-binding site of DNA gyrase as target of EGCG, the most abundant catechin from the green tea extract. Up to now several compounds targeted against the ATP-binding site of bacteria gyrase have been known but couldn't be used as drugs due to their side effects on mammalian cells.

Lead researcher Roman Jerala, the head of the Laboratory of Biotechnology at NIC explains: "We can anticipate to avoid the problem of toxicity using the compounds based on the green tea catechins, which have centuries of established safety record in the human diet."

This finding may be used to develop even more potent antibacterial compounds. Results were recently published in the Journal of Medicinal Chemistry.

Adapted from materials provided by National Institute Of Chemistry, Slovenia.




Read the rest of this entry »

Daily Science Journal (Dec. 13, 2007) — Researchers at Rensselaer Polytechnic Institute have developed a new way to seek out specific proteins, including dangerous proteins such as anthrax toxin, and render them harmless using nothing but light. The technique lends itself to the creation of new antibacterial and antimicrobial films to help curb the spread of germs, and also holds promise for new methods of seeking out and killing tumors in the human body.

Transmission electron microscope images show carbon nanotubes conjugated with anthrax toxin before (a, b) and after (c, d) exposure to ultraviolet light. This light caused the adsorbed toxin to deactivate and fall off the nanotube, which is why the structures in pictures c and d are smaller in diameter than those in pictures a and b. (Credit: Rensselaer/Ravi Kane)

Scientists have long been interested in wrapping proteins around carbon nanotubes, and the process is used for various applications in imaging, biosensing, and cellular delivery. But this new study at Rensselaer is the first to remotely control the activity of these conjugated nanotubes.


A team of Rensselaer researchers led by Ravi S. Kane, professor of chemical and biological engineering, has worked for nearly a year to develop a means to remotely deactivate protein-wrapped carbon nanotubes by exposing them to invisible and near-infrared light. The group demonstrated this method by successfully deactivating anthrax toxin and other proteins.

"By attaching peptides to carbon nanotubes, we gave them the ability to selectively recognize a protein of interest -- in this case anthrax toxin -- from a mixture of different proteins," Kane said. "Then, by exposing the mixture to light, we could selectively deactivate this protein without disturbing the other proteins in the mixture."

By conjugating carbon nanotubes with different peptides, this process can be easily tailored to work on other harmful proteins, Kane said. Also, employing different wavelengths of light that can pass harmlessly through the human body, the remote control process will also be able to target and deactivate specific proteins or toxins in the human body. Shining light on the conjugated carbon nanotubes creates free radicals, called reactive oxygen species. It was the presence of radicals, Kane said, that deactivated the proteins.

Kane's new method for selective nanotube-assisted protein deactivation could be used in defense, homeland security, and laboratory settings to destroy harmful toxins and pathogens. The method could also offer a new method for the targeted destruction of tumor cells. By conjugating carbon nanotubes with peptides engineered to seek out specific cancer cells, and then releasing those nanotubes into a patient, doctors may be able to use this remote protein deactivation technology as a powerful tool to prevent the spread of cancer.

Kane's team also developed a thin, clear film made of carbon nanotubes that employs this technology. This self-cleaning film may be fashioned into a coating that -- at the flip of a light switch -- could help prevent the spread of harmful bacteria, toxins, and microbes.

"The ability of these coatings to generate reactive oxygen species upon exposure to light might allow these coatings to kill any bacteria that have attached to them," Kane said. "You could use these transparent coatings on countertops, doorknobs, in hospitals or airplanes -- essentially any surface, inside or outside, that might be exposed to harmful contaminants."

Kane said he and his team will continue to hone this new technology and further explore its potential applications.

Details of the project are outlined in the article "Nanotube-Assisted Protein Deactivation" in the December issue of Nature Nanotechnology.

Co-authors of the paper include Department of Chemical and Biological Engineering graduate students Amit Joshi and Shyam Sundhar Bale; postdoctoral researcher Supriya Punyani; Rensselaer Nanotechnology Center Laboratory Manager Hoichang Yang; and professor Theodorian Borca-Tasciuc of the Department of Mechanical, Aerospace, and Nuclear Engineering.

The group has filed a patent disclosure for their new selective nanotube-assisted protein deactivation technology. The research project was funded by the U.S. National Institutes of Health and the National Science Foundation.

Adapted from materials provided by Rensselaer Polytechnic Institute, via EurekAlert!, a service of AAAS.




Read the rest of this entry »

Daily Science Journal (Sep. 19, 2007) — Scientists have shown for the first time that platelets, the cells needed for blood clotting, help white blood cells called neutrophils fight inflammation.

The discovery was made by Ralph Kettritz, Professor of Medicine at the Medical Faculty of the Charite and investigator at the Max Delbrueck Center for Molecular Medicine, Berlin, Germany, and colleagues. The results of the study could lead to new anti-inflammatory compounds for the treatment of inflammatory vascular injury.

"We found an entirely new mechanism by which neutrophils induce inflammation," Kettritz says. "So far, scientists have shown that platelets form clots and neutrophils can cause symptoms of inflammation, such as swelling, redness, and heat. In this study, we show that platelets and neutrophils sometimes work together to heal a wound or fight an infection."


During inflammation -- a protective reaction from the tissues following a wound or infection -- white blood cells attack bacteria and platelets form clots that close any potential wound. White blood cells called neutrophils are the first to launch an attack against the bacteria. They are attracted by substances, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), that are released at the early stages of inflammation. Once activated, neutrophils engulf and destroy bacteria and damaged tissue.

In addition to neutrophils, two other types of white blood cells, called macrophages and lymphocytes, also engage in the fight against bacteria. These cells are activated by a chemical compound called tumor necrosis factor (TNF) released by the neutrophils. Although there are several ways by which neutrophils release TNF, Kettritz and colleagues found that neutrophils can be stimulated to produce TNF in a totally new and different way.

"Usually, TNF is produced when specific chemicals bind to proteins called receptors on the surface of a neutrophil, which tells the cell that it should make TNF," Kettritz says. "This time, we found that a neutrophil can acquire receptors that are not already present on its surface and use them to stimulate the production of TNF."

The receptors, called GPIIb/IIIa, are sent to neutrophils by platelets. Like a letter sent in an envelope, these receptors are packaged in vesicles called microparticles that, when they reach a neutrophil, bind to its surface and release the receptors. Once released, the receptors are incorporated into the neutrophil's cell membrane.

Kettritz and his team also found that these newly-acquired receptors did not work alone. To stimulate neutrophils to produce TNF, the GPIIb/IIIa receptor works in tandem with the receptor for GM-CSF (the substance produced during the early stages of inflammation). The scientists found that the neutrophil produces TNF both when GPIIb/IIIa binds to a protein outside the cell called fibronectin and when the GM-CSF receptor binds to GM-CSF.

"We have shown for the first time that platelets can, by using microparticles, help other cells -- in this case, neutrophils -- respond to inflammation," Kettritz says. "We also found for the first time that receptors involved in blood clotting also trigger an inflammatory response."

These results may help devise new drugs against several types of inflammation by targeting the GPIIb/IIIa receptors acquired by neutrophils. In particular, drugs currently used to prevent blood clotting by inhibiting GPIIb/IIIa receptors on platelets may be used against inflammation.

Kettritz and colleagues tested three of these drugs -- abciximab, epifibatide, and tirofiban -- on cell cultures in which neutrophils had received the GPIIb/IIIa receptors from platelets and confirmed the drugs' effects on inflammation. The scientists showed that all three drugs inhibited the production of TNF, which reduced inflammation in these cells. These results also led the researchers to speculate that some of the beneficial effects of the three drugs on patients with acute coronary syndrome result from their anti-inflammatory properties.

If the drugs' effects are confirmed in clinical trials, they could be used against several types of inflammation that include acute vasculitis, an inflammation of blood vessels that can affect any organ in the body. Also, the drugs have been used successfully to treat acute coronary syndrome, which refers to certain types of heart attack and unstable angina. The new results show that these beneficial effects may be due not only to their anti-clotting properties, but also to their anti-inflammatory qualities.

"The results of this study are very encouraging," Kettritz says. "Although specific drugs that target GPIIb/IIIa receptor actions on neutrophils may need to be developed in the future, these three drugs can now be tested in clinical trials, which could make them -- or modified versions of them -- new anti-inflammatory drugs."

The new study, to be published in the September 21 issue of the Journal of Biological Chemistry, was selected as a "Paper of the Week" by the journal's editors, meaning that it belongs to the top one percent of papers reviewed in significance and overall importance.

Article: "Beta 2-integrins and acquired GPIIb/IIIa receptors cooperate in NF-KB activation of human neutrophils," by Birgit Salanova, Mira Choi, Susanne Rolle, Maren Wellner, Friedrich C. Luft, and Ralph Kettritz

Adapted from materials provided by American Society for Biochemistry and Molecular Biology, via EurekAlert!, a service of AAAS.




Read the rest of this entry »

Daily Science Journal (Jun. 15, 2007) — They are the largest group of white blood cells: neutrophil granulocytes kill microorganisms. Neutrophils catch microbes with extracellular structures nicknamed Neutrophil Extracellular Traps (NETs) that are composed of nucleic acid and aggressive enzymes.

Neutrophil granulocytes have trapped Shigella bacteria in NETs. (Image: Dr. Volker Brinkmann, Max Planck Institute for Infection Biology)

A group of scientists lead by Arturo Zychlinsky at the Max-Planck-Institute for Infectious Biology in Berlin, Germany discovered, how the neutrophils form this snaring network (Journal of Cell Biology, online, January 8, 2007). Once triggered, the cells undergo a novel program leading to their death. While they perish, the cells release the content of their nuclei. The nucleic acid, mingled with bactericidal enzymes, forms a lethal network outside the cell. Invading bacteria and pathogenic fungi get caught and killed in the NETs.


Every minute, several million neutrophils leave the bone marrow and are ready to defend the body of invading germs. They are the immune system’s first line of defence against harmful bacteria and migrate into the tissue at the site of infection to combat pathogens. For more than hundred years it was known that neutrophil granulocytes kill bacteria very efficiently by devouring them. After eating the germs neutrophils kill tehm with antimicrobial proteins.

The group of scientists lead by Arturo Zychlinsky at the Max-Planck-Institute for Infectious Biology discovered a second killing mechanism: neutrophil granulocytes can form web-like structures outside the cells composed of nucleic acid and enzymes which catch bacteria and kill them. The scientists were able to generate impressive micrographs of these nets. But it remained a mystery how the granulocytes could mobilise the contents of their nuclei and catapult it out of the cells.Only after lengthy live cell imaging and biochemical studies it became clear how neutrophils make NETs. The cells get activated by bacteria and modify the structure of their nuclei and granules, small enzyme deposits in the cytoplasm.

"The nuclear membrane disintegrates, the granules dissolve, and thus the NET components can mingle inside the cells", explains Volker Brinkmann, head of the microscopy group. At the end of this process, the cell contracts until the cell membrane bursts open and quickly releases the highly active melange. Once outside the cell, it unfolds and forms the NETs which then can trap bacteria.

Surprisingly, this process is as effective as devouring bacteria: "NETs formed by dying granulocytes kill as many bacteria as are eaten up by living blood cells", says Arturo Zychlinsky. Thus, neutrophils fulfil their role in the defence battle even after their deaths.

Adapted from materials provided by Max Planck Society.



Read the rest of this entry »